Employers › Sunovion Pharmaceuticals
Recordkeeping fees per participant · My 401(k) Plan · plan year 2024
$38.33
Higher than 34% of the 1,697 plans $250M to 1B that report it.
= $106,279 / 2,773
Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20250626023637NAL0008635553001, received 2025-06-26
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250626023637NAL0008635553001, received 2025-06-26
Percentiles compare this plan with the Schedule H plans $250M to 1B in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-06-26.
Administrative expenses excluding investment management, per participant
$46.95
Higher than 28% of the 2,324 plans $250M to 1B that report it.
= $130,179 / 2,773
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250626023637NAL0008635553001, received 2025-06-26
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250626023637NAL0008635553001, received 2025-06-26
Administrative expenses per participant
$79.64
Higher than 44% of the 2,405 plans $250M to 1B that report it.
= $220,834 / 2,773
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250626023637NAL0008635553001, received 2025-06-26
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250626023637NAL0008635553001, received 2025-06-26
Administrative expenses as a share of assets
0.035%
Higher than 21% of the 2,407 plans $250M to 1B that report it.
= $220,834 / $634,069,891
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250626023637NAL0008635553001, received 2025-06-26
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250626023637NAL0008635553001, received 2025-06-26
Employer contributions per participant
$5,788
Higher than 79% of the 2,457 plans $250M to 1B that report it.
= $16,049,483 / 2,773
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250626023637NAL0008635553001, received 2025-06-26
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250626023637NAL0008635553001, received 2025-06-26
Employer share of total contributions
32.2%
Higher than 54% of the 2,459 plans $250M to 1B that report it.
= $16,049,483 / $49,824,467
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250626023637NAL0008635553001, received 2025-06-26
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250626023637NAL0008635553001, received 2025-06-26
Plan terms are described in Sunovion Pharmaceuticals Inc.'s SEC filings: Form 10-K filed 2009-02-27. No term could be quoted from them with the required precision.
2E profit-sharing · 2F ERISA 404(c) plan · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2T default investment (QDIA) · 3D IRS pre-approved plan · 3H controlled-group sponsor · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20250626023637NAL0008635553001, received 2025-06-26
| Field | Value | Source |
|---|---|---|
| Plan sponsor | SUMITOMO PHARMA AMERICA, INC. | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Plan name | MY 401(K) PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Sponsor EIN / plan number | 22-2536587 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Sponsor location | MARLBOROUGH, MA | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Industry (business code) | 325410, Manufacturing | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Filing received | 2025-06-26 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Participants, beginning of year | 3,318 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Active participants | 1,141 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Participants, end of year | 2,832 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Participants with an account balance | 2,773 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Total assets, beginning of year | $647,233,051 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Total assets, end of year | $634,069,891 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Net assets, end of year | $634,069,891 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Total income | $147,226,172 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Net income | $-13,163,160 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Employer contributions | $16,049,483 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Participant contributions | $25,690,935 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Other contributions (incl. rollovers) | $8,084,049 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Total contributions | $49,824,467 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Benefit payments | $160,028,811 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Total expenses (incl. benefit payments) | $160,389,332 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Total administrative expenses | $220,834 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Contract administrator fees | $2,400 | Schedule H, line 2i(2); CONTRACT_ADMIN_FEES_AMT pos 106; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Recordkeeping fees | $106,279 | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| IQPA audit fees | $21,500 | Schedule H, line 2i(4); IQPA_AUDIT_FEES_AMT pos 161; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Investment advisory and management fees | $90,655 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Administrative expenses excluding investment management | $130,179 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Held in master trusts | $0 | Schedule H, line 1c(11) col (b); INT_MASTER_TR_EOY_AMT pos 53; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Held in common/collective trusts | $97,081,179 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Held in mutual funds | $535,035,175 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20250626023637NAL0008635553001, received 2025-06-26 |
| Independent auditor | CARON & BLETZER PLLC | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20250626023637NAL0008635553001, received 2025-06-26 |
Position = column in the DOL layout for form year 2024. Filing 20250626023637NAL0008635553001, received 2025-06-26.
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| FIDELITY INVESTMENTS INSTITUTIONALrecordkeeper | RECORDKEEPER | 37 Participant loan processing; 64 Recordkeeping fees; 65 Account maintenance fees | $108,679 | yes |
| STRATEGIC ADVISORS, INC. | ADVISOR | 27 Investment advisory (plan) | $90,655 | no |
| CARON & BLETZER PLLC | ACCOUNTANT/AUDITOR | 10 Accounting (including auditing) | $21,500 | no |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20250626023637NAL0008635553001, received 2025-06-26.
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $647,233,051 | $634,069,891 | -2.0% |
| Participants with a balance | 3,193 | 2,773 | -13.2% |
| Administrative expenses | $245,357 | $220,834 | -10.0% |
| Recordkeeping fees per participant | $13.71 | $38.33 | 179.6% |
| Employer contributions | $15,949,837 | $16,049,483 | 0.6% |
Prior filing 20241204202439NAL0008785410001, received 2024-12-04; the plan years are contiguous.
Sponsor name as filed: SUMITOMO PHARMA AMERICA, INC.; SEC registrant: Sunovion Pharmaceuticals Inc. (CIK 877357, matched by EIN).